Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, B-Cell, Marginal Zone 14Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma × orelabrutinib × Clear all
NCT07441993 2026-03-02

MZL-IIT-O

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06015464 2023-08-29

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

The First Affiliated Hospital with Nanjing Medical University

Unknown
81 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡